1.Pfizer Inc. In 2018, Pfizer Inc. revenue in the U.S. market was $25.32 billion, which is a decrease of 2.75% compared with 2017. Pfizer had the highest revenue in the U.S. market, accounting for 47.21% of total sales in fiscal 2018
2. Johnson & Johnson Johnson & Johnson had revenue of $23.28 billion in the U.S. market, up 8.43% compared to 2017. The U.S. company's sales were $41.9 billion in 2018, $39.9 billion in 2017, and $37.8 billion in 2016
3. Roche Holding Company Roche Holding Company's revenues from the U.S. market were $22.76 billion in fiscal year 2018, an increase of 13.35 percent from fiscal year 2017. In the U.S., sales of products led by Ocrevus, Perjeta and Lucentis grew rapidly
4, AbbVie Inc. AbbVie Inc. reported U.S. revenues of $21.52 billion in fiscal 2018, up 17.9% from fiscal 2017. The company's global sales were impacted by the launch of several direct biosimilars, which were marketed at much cheaper prices than AbbVie, leading to a decline in its sales in Europe and other international markets
5. Amgen's U.S. revenues grew 1.27 percent to $18.28 billion in 2017, and the company's global product sales grew 8 percent. Recently launched new products including Repatha, Prolia, KYPROLIS and XGEVA achieved double-digit growth.6. Novartis Novartis reported revenues of $17.56 billion in fiscal year 2018, an increase of 3.69% over fiscal year 2017. Novartis has decided to abandon its Alcon eye care division and U.S. generics business to focus on new high-tech drugs
7. Merck & Co. Merck & Co. reported revenues of $16.6 billion in fiscal 2018, up 4.76 percent from fiscal 2017. Merck's total revenue is expected to grow 5.68 percent to $44.7 billion by fiscal 2021.In 2021, Merck said it will report non-GAAP earnings per share in the range of $4.57 to $4.72 and global sales in the range of $43.2 billion to $44.7 billion
8, Gilead Sciences, Inc. gilead sciences, Inc. book a U.S. biopharmaceutical company, the company develops and commercializes innovative drugs. Gilead's primary areas of focus include HIV, liver disease, hematology/oncology, and inflammatory/respiratory diseases. Gilead had revenues of $16.2 billion in fiscal year 2018
9, Sanofi Limited In 2018, Sanofi Limited had registered drug revenues of $13.15 in the U.S. market, a decrease of 2.66% compared to 2017
10, Bristol-Myers Squibb Company In 2018, Bristol-Myers Squibb had revenues of $12.58 billion dollars, an increase of 11% from fiscal year 2017. Bristol-Myers Squibb's fourth-quarter revenue in the U.S. rose 16 percent to $3.3 billion compared with the same period last year.
Japan's pharmaceutical industry is quite developed, the Japanese people's rigorous attitude towards work is particularly suitable for the pharmaceutical industry, in the world's top50 or top100 list of pharmaceutical companies in Japan usually dominate a number of seats, second only to the U.S., which Daiichi Sanki***, Astellas, Eisai, Takeda, Otsuka is the top five giants of Japan's pharmaceuticals, the world's top.
r
1. Sun Pharmaceuticals, 2. Lupin LupinLtd, 3. Dr. Reddy's LaboratoriesDr. Reddy's Laboratories